Highly immunogenic peptides derived from the human immunodeficiency virus V2 region

Patent metadata

Field	Value
Publication number	US-9969782-B2
Application number	US-201414508669-A
Country	US
Kind code	B2
Filing date	Oct 7, 2014
Priority date	Oct 7, 2013
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form β-hairpin structure. A further aspect of the present invention is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 15, or at least a contiguous 5 amino acid fragment thereof, capable of folding into an alpha-helical structure. These immunogenic peptides can be inserted into an immunogenic scaffold protein to form an immunogenic polypeptide. The immunogenic peptides or immunogenic polypeptides can be used in an immunogenic vaccine composition and in methods of inducing a neutralizing antibody response, or inducing a protective and non-neutralizing antibody response, or protective antibodies, against HIV-1 gp120 in a subject. Isolated antibodies and methods of detecting are also disclosed.

First claim

What is claimed is:

1. An isolated immunogenic peptide consisting of the amino acid sequence corresponding to SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.

2. An immunogenic vaccine composition comprising:
the isolated immunogenic polypeptide of claim 1 and
an immunologically and pharmaceutically acceptable vehicle or excipient.

3. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 16.

4. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 17.

5. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 18.

6. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 19.

7. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 20.

8. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 21.

9. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 22.

10. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 23.

11. The isolated immunogenic peptide of claim 1 , wherein the isolated immunogenic peptide consists of the amino acid sequence corresponding to SEQ ID NO: 24.

Assignees

• Univ New York

Inventors

• Cardozo Timothy

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title